<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H8225EFB14F7B4E3B9773C3814D5879F9" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 3348 IH: Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-07-20</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 3348</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170720">July 20, 2017</action-date><action-desc><sponsor name-id="P000608">Mr. Peters</sponsor> (for himself, <cosponsor name-id="B001296">Mr. Brendan F. Boyle of Pennsylvania</cosponsor>, <cosponsor name-id="M001198">Mr. Marshall</cosponsor>, and <cosponsor name-id="R000598">Mr. Rothfus</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To expand the tropical disease product priority review voucher program to encourage treatments for
			 the Middle East respiratory syndrome.</official-title></form>
	<legis-body id="H87A0AC1E9E6D47C0BA73A4BE0A32F90D" style="OLC">
 <section id="HCB385D0F1BEE43779A9B5E8AB544EAFB" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act</short-title></quote>.</text> </section><section id="H82ADC8C150D24741BB0029143CDAADF4"><enum>2.</enum><header>Expanding tropical disease product priority review voucher program to encourage treatments for Middle East respiratory syndrome</header><text display-inline="no-display-inline">Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360n">21 U.S.C. 360n(a)(3)</external-xref>) is amendedâ€”</text>
 <paragraph id="H2C021A163F2240F38D9BB9E7B3725E1B"><enum>(1)</enum><text>by redesignating subparagraph (S) as subparagraph (T); and</text> </paragraph><paragraph id="HECF8B27C73ED482984E18C4FA3400BC5"><enum>(2)</enum><text>by inserting after subparagraph (R) the following:</text>
				<quoted-block id="HE65DD76C459241EAB4273477BDB5B4E3" style="OLC">
 <subparagraph id="HEBC0B9628BE348659EAE480167825ADA"><enum>(S)</enum><text display-inline="yes-display-inline">Middle East respiratory syndrome.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block> </paragraph></section></legis-body></bill> 

